Biology Atlas

Map / The cascade

step · intermediate · partly written

Clinical

One step of the screening cascade walk-through, from disease to clinic.

What is done

Testing in people in phases defined by regulation. Phase 1 is the first introduction into humans, to learn metabolism, pharmacologic actions and side effects with increasing dose, generally in the range of 20 to 80 subjects. Phase 2 is controlled studies of effectiveness and short-term risks, usually no more than several hundred. Phase 3 is expanded trials for effectiveness, safety and benefit-risk, usually several hundred to several thousand. Kept thin on purpose: queue item 6 will deepen it. 1

Established

Proves

Phase 1 aims at human pharmacokinetics, pharmacology and tolerability, with early evidence of effect if possible; Phases 2 and 3 are the controlled evidence on effectiveness and the benefit-risk balance behind labelling. 1

Established

Cannot prove

That a measured change in the target means benefit: tominersen lowered mutant huntingtin in spinal fluid and the every-2-months arm still did worse than placebo (see the modality notes). 2

Reported, not yet replicated

Regulators require

An IND may be submitted for one or more phases, and the phases are generally conducted in sequence though they may overlap. Marketing-approval requirements are not covered here and belong to report 6. 1

Established

Reports

Modality notes

Lowering the target is a surrogate, not benefit

Tominersen lowered mutant huntingtin in the spinal fluid and the every-2-months arm still did worse than placebo; revusiran stopped on a mortality imbalance with no causative mechanism found. Readouts in oligo and RNAi trials must be read with their denominators and assessors. 23

See: Tominersen, Revusiran, Antisense oligonucleotide (ASO), siRNA

Reported, not yet replicated

Cell and gene products have their own failure modes in the clinic

The 1999 adenovirus trial death and the JCAR015 cerebral-oedema deaths are cases where the product or its conditioning regimen caused fatal toxicity in the clinic; see the drug records for the sources and limits. 4

See: 1999 adenoviral gene transfer trial for OTC deficiency, JCAR015, Gene therapy, CAR T cell therapy

Reported, not yet replicated

Still open here

Not yet written: Costs, Assays, ML role, Scenarios.

Linked from

Sources

  1. US Food and Drug Administration. Phases of an investigation (21 CFR 312.21). Electronic Code of Federal Regulations, Title 21, Part 312 (2026). regulatory, not peer reviewed; opened 2026-11-17 all records citing this
  2. F. Hoffmann-La Roche Ltd (sponsor). GENERATION HD1 (BN40423) final results: plain-language summary, September 2023. Roche forpatients (2023). organisation-page, not peer reviewed; opened 2026-11-17 all records citing this
  3. Judge DP, et al.. Phase 3 Multicenter Study of Revusiran in Patients with Hereditary Transthyretin-Mediated (hATTR) Amyloidosis with Cardiomyopathy (ENDEAVOUR). Cardiovasc Drugs Ther (2020). paper; opened 2026-11-17 all records citing this
  4. Raper SE, Chirmule N, Lee FS, et al.. Fatal systemic inflammatory response syndrome in a ornithine transcarbamylase deficient patient following adenoviral gene transfer. Molecular Genetics and Metabolism (2003). paper; opened 2026-11-17 all records citing this
History of this record (6)

This record has been changed 6 times, on the dates below. The note kept against each change is written for the people who maintain the atlas, in their own shorthand, so it is not shown here; it is in the record itself.

Order
12
Stage
clinical
Status
partly written
Last updated
2026-11-17
Record
content/cascade/clinical.json